Editorial

In ongoing work associated with the Jefferson College of Population Health (JCPH), I am engaged with a score of public and private sector organizations that are seeking to further define our field and to shape its future direction. I could not help but notice that in the past few weeks alone, in terms of consolidation, we have been at the “eye of the storm.” Allow me to share some specific examples of market consolidation, and then to offer some prognostication regarding the future.
For more than 2 years, I have had the privilege of participating in a very important national task force that is sponsored by the National Quality Forum (NQF) in Washington, DC. The task force is charged with giving input on a critical national priority, namely, improving population health by working with communities.
“I’m guessing that, like me, most of our readers have not heard the term ‘hassle map,’” says Dr Nash in this editorial. He reviews a recent white paper titled, “The Marketplace Revolution: Shattering the Foundation of the $3 Trillion Sick-Care Marketplace,” authored by Tom Main and Adrian Slywotzky.
Have you ever heard of the term, in silico? It means “performed on a computer or via computer simulation.” This term is an introduction to a potentially emerging trend and a powerful tool for the future.
Healthcare in the United States has experienced a tremendous amount of reform and innovation, especially in the past 10 years, with an emphasis on improving value.
ICER is a Boston-based independent nonprofit organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures. The organization represents perhaps the first major US attempt to complete and publicly share comprehensive health technology assessments.
As acquisition costs for inpatient-related drugs continue to climb, it is time to revisit the work of an important committee outside of the P&T structure, namely, the PharmacoEconomics and Clinical Effectiveness (PEACE) committee.
Within weeks of graduating from medical school in July 1981, my physician wife and I moved to Philadelphia to begin our internships. Philadelphia seemed a world away from suburban Long Island, New York, where I grew up, but it has been my home for most of my professional life.
Whatever the reason, I’m more reflective these days than ever. Late spring and early summer in Philadelphia was a time for more reflection as our city hosted both the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and The Bio International Convention (BIO) 2015 meeting.
As the healthcare delivery system shifts its focus from “volume” to “value,” it must also change the way executives and physician leaders are paid.
Page 3 of 8
Results 21 - 30 of 80
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME